



Extra-Gastrointestinal Stromal Tumors (EGISTs) : A Case Report and Review of Literature

S. N. Jatal ^{a++*}, Sudhir Jatal ^{a,b#}, Ajay Punpale ^{c†}
and Sachin Ingle ^{c‡}

^a Jatal Hospital and Research Centre, Latur, India.

^b Tata Hospital, Mumbai, India.

^c MIMSR Medical College, Latur, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/118445>

Case Report

Received: 07/04/2024

Accepted: 11/06/2024

Published: 15/06/2024

ABSTRACT

Gastrointestinal stromal tumor (GIST) represent less than 1% of all gastro intestinal stromal tumors (GISTS) and are main in the stomach and small intestine. Mesenteric GIST is rarely reported as they constitute 5 to 10% of GIST. It originates from the intestinal cells of Cajal. GISTS that develops outside the gastrointestinal tract and have no connection with the intestinal wall or serosal surface of the gastrointestinal tubular organs.

An extra-intestinal gastrointestinal stromal tumors (EGITS) they have similar morphological and immune-histological characteristics as GISTS. Surgical resection is the main stay of treatment. Post-operative use to imatinib, delay the recurrence and improves to survival rate.

⁺⁺ M.S. F.I.C.S., FAIS, FIGES;

[#] Fellow in Colorectal Cancer;

[†] Oncosurgeon and Associate Professors;

[‡] Professor;

*Corresponding author: E-mail: jatalhospital@gmail.com;

We report a rare case of mesenteric extra-gastrointestinal stromal tumor (EGITS) in a 50 years old female and discuss the course of clinical presentation, diagnosis and management.

Keywords: *Gastrointestinal stromal tumor; mesenteric GIST; surgical resection; imatinib.*

1. INTRODUCTION

“Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract that arise from the interstitial cells of Cajal. The term GIST was coined by Mazur and Clark in 1983. The annual incidence of GISTs is approximately 15 cases per million people, and they are mostly seen in patients older than 50 years, with a male-to-female ratio of approximately 1:1. Complete surgical resection offers a better chance of survival. Imatinib, a tyrosine kinase inhibitor, plays a significant role postoperatively and is associated with a good prognosis” [1-6].

“Extra-gastrointestinal stromal tumors (EGISTs) are extremely rare, accounting for only 5% of all GISTs and less than 0.05% of all gastrointestinal tumors. Both GISTs and EGISTs share the same molecular biology, histology, and immunohistochemical behaviour. Immunohistochemical tests for CD117 (C-kit protein) and CD34 are essential for diagnosis. Recommended imaging studies include CT, MRI, and PET scans. The standard treatment for localized, resectable, and non-metastatic GISTs and EGISTs is surgery [7]. Recognizing the rarity of EGIST cases is crucial. Several primary sites of EGISTs have been reported, including the mesentery, omentum, peritoneum, pancreas, and retroperitoneum. A total of 114 cases of mesenteric GISTs have been documented in the literature”. [8,3,9].

2. CASE REPORT

We present the case of a 50-year-old female admitted to our centre on 20/10/2018 with

complaints of an abdominal lump and pain. On clinical examination, all vital parameters were within normal limits. Abdominal examination revealed a well-defined, tender, right-sided abdominal mass that was freely mobile. Blood tests, including a full blood count, urea and electrolyte levels, and liver function tests, were normal. An abdominal ultrasonography reported a 4x3 cm mass with a solid appearance and well-defined wall. CT scan confirmed a large, well-defined 4x3 cm mass with heterogeneous densities and areas of necrosis, diagnosed as a mesenteric mass.

A surgical approach was decided upon, involving an open laparotomy through a midline incision. Intraoperatively, the tumor was found to be arising from the small bowel mesentery and was closely related to small bowel loops. The tumor was free, spherical in shape, 4x3 cm in size, with smooth margins and no adhesions to surrounding structures. The tumor was localized, so complete surgical resection with anastomosis of the small bowel was performed.

Pathological examination of the specimen revealed a 4x3 cm spherical mass with smooth margins. Histopathologically, the tumor showed spindle cells with a low mitotic rate, and the CD117 antigen test was positive for GIST. The patient was referred to a cancer centre, and Post-operative use of imatinib delays recurrence and improves survival rate. After a follow-up period of 5 years postoperatively, the patient is healthy with no recurrence of the disease [Figs. 1-8].




Fig. 1. CT abdomen showing a large, solid heterogenous well defined mass of size 4x3 cm




Fig. 2. Intraoperative photograph showing mesenteric GIST




Fig. 3. Intraoperative photograph showing mesenteric GIST of size 4x3 cm



Fig. 4. Intraoperative photograph showing mesenteric GIST with surgical resection




Fig. 5. Intraoperative photograph showing mesenteric GIST with surgical resection




Fig. 6. Gross specimen of mesenteric GIST of size 4x3 cm spherical mass with regular margins



Fig. 7. Intraoperative photographs showing ilio-ileal anastomosis




Fig. 8. Spindle cell GIST with low mitosis




Fig. 9. Spindle cell GIST positive for CD 117 antigen test

3. DISCUSSION AND REVIEW OF LITERATURE

“Extra-gastrointestinal GISTs (EGISTs) are GISTs that have no connection with the intestinal wall or the serosal surface of gastrointestinal tubular organs. These tumors are extremely rare, accounting for only 5% of all GISTs” [1,2].

“Miettinen et al were the first to describe EGISTs in 1995, they reported a series of omental and mesenteric stromal tumor positive for CD 117. EGISTs similar to GISTs originate from intestinal cells of Cajal (ICC). ICC are pacemaker cells that control the peristalsis in the gastrointestinal tract. EGIST mostly occur intra abdominally and in the retroperitoneum” [3,9,10].

“Clinically, symptoms vary depending on the location of the EGIST. Patients may be asymptomatic and incidentally diagnosed during routine examination for other medical conditions or may have typical symptoms such as abdominal pain, abdominal mass or distension feng et al reported the above symptoms. Diagnosis is through tissue histopathology with immunohistochemical standing CD 117 positive test. Feng et al examined the clinicopathological features and prognosis of mesenteric GISTS in 114 mesenteric GIST. Histopathological EGIST, express markers such a CD 34, C-kit, CD 117, DOG -1 and PKC-0” [3,9,11].

“Treatment for EGSIT depends a staging. For localized tumors, the standard treatment involves

complete surgical excision of the tumor along with negative margins. For locally advanced, inoperable or metastatic disease, standard treatment is imatinib, a tyrosine kinase inhibitor” [9,12].

“Mesenteric GISTS have poorer outcomes compared to classical GISTS. Mesenteric GISTS had poor outcomes with fewer survival compared to gastric GISTS. Feng et al noted that tumor size, mitotic activity index, histological type and prognosis of mesenteric GISTS was worse than that of gastric GIST. The study also noted most mesenteric GISTS exceeding 10 cm in diameter, 5/50 HPF in the mitotic index, were high risk with poorer prognosis” [9,10].

“In high risk category patient is recommended follow up with serial CT scan in addition to surgery and targeted therapy approximately 10 years from imatinib therapy. Sunitinib and ponatinib are other options for resistance or partial response to imatinib” [4,10,13].

4. CONCLUSION

Mesenteric GIST (EGIST) is a rare condition. It presents as an abdominal mass and can be mistaken for mesenteric tumors or growths. Large mass more than 5 cm, incomplete resection margins and central necrosis are all poor indices for survival and result in high recurrence.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology.

Details of the AI usage are given below:

1. Chat-GPT

CONSENT

As per international standards or university standards, patient(s) written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standards or university standards written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Gregorio Arellano-Gutiérrez, Edwin Leopoldo Maldonado-García, Primary extra-gastrointestinal stromal tumor (EGIST) of the mesentery: Case report and review of literature, *Annals of Medicine and Surgery*; 2018. Available: <https://doi.org/10.1016/j.amsu.2020.11.020>
2. Rajalakshmi R, Rajakumar V. A case of mesenteric gastro intestinal stromal tumors: a diagnostic dilemma. *International Surgery Journal*. 2022;9: 2076. DOI:10.18203/2349-2902.isj20223176
3. AK Das, Tarjina Begum, Bedanta Barman, Prajna Anirvan, Mesenteric GIST: A case report, *The Journal of Medical Research* Research (medicinearticle.com) 2018;4(1):4-6.
4. Abood HBA, Albalawi AND, AlEnazi HO, Almuhanha MM, Busaad NO, Jarad RG. Alkhamis A, Alsharif MS, Alahdal SM, Alqahtani MAS, Alhakamy DAS, AR. Alraqibah SA. Overview on Gastrointestinal Stromal Tumor; A Review, *Journal of Pharmaceutical Research International*. 2021;33(56B):29–36. Doi: 10.9734/jpri/2021/v33i56B33925
5. Bhadani PP, Singh A., Gupta GK, Parasar K. An unusual appearance of cystic gastrointestinal stromal tumor of small intestine - A case report and brief review of literature. *Journal of Advances in Medicine and Medical Research*. 2022;34(20):282-88. Available: <https://doi.org/10.9734/jammr/2022/v34i2031496>.
6. Caterino S, Lorenzon L, Petrucciani N, Iannicelli E, Pillozzi E, Romiti A, Ziparo, V. Gastrointestinal stromal tumors: Correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. *World Journal of Surgical Oncology*. 2011;9:1-10.
7. Abidoye O, Johnson A Extremely Aggressive Mesenteric Extra gastrointestinal Stromal Tumor: A Case Report and Literature Review. *Cureus* 2022;14(3):e23108.

- DOI:10.7759/cureus.23108
8. Ramani AS, Huske G, Noronha FP. A Rare Case of Mesenteric Gastrointestinal Stromal Tumor Presenting as Acute Abdomen. Niger J Surg. 2017;23(1): 71-72.
DOI: 10.4103/1117-6806.199960. PMID: 28584517; PMCID: PMC5441222.
 9. Feng, F, Feng, B, Liu, S, Liu, Z, Xu, G, Guo, M, Lian, X, Fan, D, & Zhang, H. Clinicopathological features and prognosis of mesenteric gastrointestinal stromal tumor: evaluation of a pooled case series. Oncotarget 2017 Jul 11;8(28):46514-46522
 10. Gupta, N., Mittal, S., Lal, N. et al. A rare case of primary mesenteric gastrointestinal stromal tumor with metastasis to the cervix uteri. World J Surg Onc. 2007;5: 137.
Available:https://doi.org/10.1186/1477-7819-5-137
 11. Tiwari, A. , Choudhary, A. , Khawal, H. , Chaudhary, P. and Arora, M. (2013) Primary Extra-Gastrointestinal Stromal Tumor (GIST) arising from mesentery of small bowel and presenting as abdominal mass: A rare entity. Open Journal of Gastroenterology. 2013;3:267-271.
DOI: 10.4236/ojgas.2013.35045.
 12. Gaillard F, Niknejad M, Knipe H, et al. Gastrointestinal stromal tumor. Reference article, Radiopaedia.org
Available:https://doi.org/10.53347/rID-6758 (Accessed on 30 May 2024).
 13. Engin G, Asoglu O, Kapran Y. et al. A gastrointestinal stromal tumor with mesenteric and retroperitoneal invasion. World J Surg Onc. 2007;5:121.
Available:https://doi.org/10.1186/1477-7819-5-121

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/118445>